Figure 2 Aβ-PET scans obtained using different tracers

Slides:

Advertisements

Similar presentations

Risk of Developing Alzheimer’s Disease in Persons with MCI

Advertisements

Table 3 Limb-girdle muscular dystrophy standardized data collection form and HPO mapping Thompson, R. & Straub, V. et al. (2016) Limb-girdle muscular dystrophies.

Date of download: 6/3/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Mechanism of Amyloid Removal in Patients With Alzheimer.

A case of Alzheimer's disease following mild traumatic brain injury

Rosa Maria Moresco University of Milan Bicocca

Copyright © 2004 American Medical Association. All rights reserved.

Nat. Rev. Neurol. doi: /nrneurol

The Pattern of Brain Amyloid Load in Posterior Cortical Atrophy Using 18F-AV45: Is Amyloid the Principal Actor in the Disease Dement Geriatr Cogn Disord.

Imaging AD Progression Amyloid Imaging Agents.

Nat. Rev. Neurol. doi: /nrneurol

Figure 3 Life expectancy at birth in all countries included

Figure 2 Systemic abnormalities in AD

Figure 2 The US Centers for Disease Control and

Figure 4 Time course of the development of physiological changes

Alzheimer Disease Mayo Clinic Proceedings

Figure 1 Carotid artery inflammation detected using 18F-FDG-PET

Figure 2 Overview of risk factors for Parkinson disease dementia

Nat. Rev. Neurol. doi: /nrneurol

Figure 2 Patterns of brain atrophy in Alzheimer disease

Amyloid Imaging for Alzheimer's Disease in Practice

Nat. Rev. Neurol. doi: /nrneurol

Nat. Rev. Neurol. doi: /nrneurol

Nat. Rev. Neurol. doi: /nrneurol

Reisa Sperling, Elizabeth Mormino, Keith Johnson Neuron

Nat. Rev. Neurol. doi: /nrneurol

Nat. Rev. Neurol. doi: /nrneurol

Figure 3 Proportion of patients for whom NEDA

Figure 1 Diagnostic tiers of Parkinson disease as single disease

Figure 2 Grey matter atrophy in FTD

Nat. Rev. Neurol. doi: /nrneurol

Figure 1 Principles of therapeutic ultrasound

Figure 3 Ascending pain pathways and the brain regions involved

A patient with early Alzheimer disease, 77 years of age, Mini-Mental State Examination score = 25. A patient with early Alzheimer disease, 77 years of.

Figure 1 Clinical correlates of neurodegeneration in MS

Volume 77, Issue 2, Pages (January 2013)

Figure 3 Genetic pleiotropy in ALS

Nat. Rev. Neurol. doi: /nrneurol

Chris Hyde Exeter Test Group.

Figure 4 11C-PK11195-PET scans showing the evolution of neuroinflammation in a patient after stroke Figure 4 | 11C-PK11195-PET scans showing the evolution.

Nat. Rev. Neurol. doi: /nrneurol

Figure 2 Carotid artery inflammation detected using 68Ga-DOTATATE-PET

Figure 3 VEGF in neurodegenerative disease

Figure 6 Combining population-wide and high-risk strategies

Nat. Rev. Neurol. doi: /nrneurol

Figure 2 Logistical requirements for autologous

Figure 3 Potential interplay between physiological

Figure 1 Clinical aspects of LGMD subtypes

Advances in the War on Alzheimer's

Figure 1 Tau PET images in patients with Alzheimer disease

Biomarker Modeling of Alzheimer’s Disease

Figure 2 Comparison between noncarriers (−) and carriers (+) of the minor allele of rs (CYP2C19)‏ Comparison between noncarriers (−) and carriers.

In vivo tau imaging: Obstacles and progress

Nat. Rev. Neurol. doi: /nrneurol

Figure 1 Timing of the effects of deep brain stimulation

Figure 5 Interaction between infarction and amyloid deposition

Figure 1 Flortaucipir PET MUBADA/PERSI SUVr at baseline, 9 and 18 months for individual subjects. Each subject is ... Figure 1 Flortaucipir PET MUBADA/PERSI.

Figure 1 [18F]florbetapir standardized uptake value ratio analytical method [18F]florbetapir standardized uptake value ratio analytical method Flowchart.

Nat. Rev. Neurol. doi: /nrneurol

Figure 3 Blood–brain barrier breakdown promotes neurodegeneration

Figure 2 A case of early-onset PSD

Longitudinal uncoupling of cerebral perfusion, glucose metabolism, and tau deposition in Alzheimer's disease Antoine Leuzy, Elena Rodriguez-Vieitez,

The influence of biological and technical factors on quantitative analysis of amyloid PET: Points to consider and recommendations for controlling variability.

Figure 2 Global tau-PET distribution in familial prion disease mirrors the distribution seen in Alzheimer disease Global tau-PET distribution in familial.

Florbetaben PET imaging to detect amyloid beta plaques in Alzheimer's disease: Phase 3 study Osama Sabri, Marwan N. Sabbagh, John Seibyl, Henryk Barthel,

Figure 2 Network connections of the hypothalamus

Cerebral hypoperfusion is not associated with an increase in amyloid β pathology in middle-aged or elderly people Oskar Hansson, Sebastian Palmqvist,

Fig. 1. AD biomarker levels in the cerebrospinal fluid of iNPH, AD, and CN subjects. Box plots of Aβ42 (A), Aβ40 (B), Aβ42/Aβ40 ratio (C), t-tau (D),

Fig. 2. Correlation between Aβ42 and Aβ40 levels in iNPH, AD, and CN subjects. The scatter plot shows the correlation between Aβ42 and Aβ40 levels. Representative.

Suzanne E. Schindler, Julia D. Gray, Brian A

Fig. 1. Pedigree of the patient's family and brain MR images of the cousin of the patient and MR and Pittsburgh compound-B (PiB) positron emission tomography.

Presentation transcript:

Figure 2 Aβ-PET scans obtained using different tracers Figure 2 | Aβ-PET scans obtained using different tracers. Surface projection images from five patients with Alzheimer disease (AD), obtained with different amyloid-β (Aβ)-PET radiotracers: 11C-Pittsburgh compound B (PiB), 18F-florbetapir, 18F-florbetaben, 18F-flutemetamol and 18F-NAV4694. Images show typical patterns of tracer retention associated with AD, with the highest retention in the frontal, temporal and posterior cingulate cortices reflecting the location of Aβ deposits in the brain. Three of these Aβ-PET tracers, florbetapir, flutemetamol and florbetaben, are approved for clinical use by the FDA and European Medicines Agency. Images generated through CapAIBL (https://capaibl-milxcloud.csiro.au) Commonwealth Scientific and Industrial Research Organisation (CSIRO) Biomedical Imaging Group. SUVR, standardized uptake value ratio. Villemagne, V. L. et al. (2018) Imaging tau and amyloid‑β proteinopathies in Alzheimer disease and other conditions Nat. Rev. Neurol. doi:10.1038/nrneurol.2018.9